HIMS Quote, Financials, Valuation and Earnings

Grove Collaborative Holdings has a net margin of 18.82% compared to Hims & Hers Health's net margin of -2.77%. Hims & Hers Health's return on equity of 27.83% beat Grove Collaborative Holdings's return on equity of -125.41%.

Hims & Hers Health has a consensus price target of $25.21, signalling downside risk potential of -5.33%. On the other hand Grove Collaborative Holdings has an analysts' consensus of -- which suggests that it could grow by 74.83%. Given that Grove Collaborative Holdings has higher upside potential than Hims & Hers Health, analysts believe Grove Collaborative Holdings is more attractive than Hims & Hers Health.

Hims & Hers Health has a beta of 1.309, which suggesting that the stock is 30.866% more volatile than S&P 500. In comparison Grove Collaborative Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grove Collaborative Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health pays -- of its earnings as a dividend. Grove Collaborative Holdings pays out -- of its earnings as a dividend.

Hims & Hers Health quarterly revenues are $401.6M, which are larger than Grove Collaborative Holdings quarterly revenues of $48.3M. Hims & Hers Health's net income of $75.6M is higher than Grove Collaborative Holdings's net income of -$1.3M. Notably, Hims & Hers Health's price-to-earnings ratio is 60.52x while Grove Collaborative Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 4.88x versus 0.24x for Grove Collaborative Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Kenvue has a net margin of 18.82% compared to Hims & Hers Health's net margin of 9.82%. Hims & Hers Health's return on equity of 27.83% beat Kenvue's return on equity of 9.94%.

Hims & Hers Health has a consensus price target of $25.21, signalling downside risk potential of -5.33%. On the other hand Kenvue has an analysts' consensus of -- which suggests that it could grow by 16.21%. Given that Kenvue has higher upside potential than Hims & Hers Health, analysts believe Kenvue is more attractive than Hims & Hers Health.

Hims & Hers Health has a beta of 1.309, which suggesting that the stock is 30.866% more volatile than S&P 500. In comparison Kenvue has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kenvue offers a yield of 3.82% to investors and pays a quarterly dividend of $0.21 per share. Hims & Hers Health pays -- of its earnings as a dividend. Kenvue pays out 874.64% of its earnings as a dividend.

Hims & Hers Health quarterly revenues are $401.6M, which are smaller than Kenvue quarterly revenues of $3.9B. Hims & Hers Health's net income of $75.6M is lower than Kenvue's net income of $383M. Notably, Hims & Hers Health's price-to-earnings ratio is 60.52x while Kenvue's PE ratio is 38.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 4.88x versus 2.63x for Kenvue. Usually stocks with elevated PS ratios are considered overvalued.

The Beauty Health has a net margin of 18.82% compared to Hims & Hers Health's net margin of -23.21%. Hims & Hers Health's return on equity of 27.83% beat The Beauty Health's return on equity of -41.24%.

Hims & Hers Health has a consensus price target of $25.21, signalling downside risk potential of -5.33%. On the other hand The Beauty Health has an analysts' consensus of -- which suggests that it could grow by 4.04%. Given that The Beauty Health has higher upside potential than Hims & Hers Health, analysts believe The Beauty Health is more attractive than Hims & Hers Health.

Hims & Hers Health has a beta of 1.309, which suggesting that the stock is 30.866% more volatile than S&P 500. In comparison The Beauty Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Beauty Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health pays -- of its earnings as a dividend. The Beauty Health pays out -- of its earnings as a dividend.

Hims & Hers Health quarterly revenues are $401.6M, which are larger than The Beauty Health quarterly revenues of $78.8M. Hims & Hers Health's net income of $75.6M is higher than The Beauty Health's net income of -$18.3M. Notably, Hims & Hers Health's price-to-earnings ratio is 60.52x while The Beauty Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 4.88x versus 0.64x for The Beauty Health. Usually stocks with elevated PS ratios are considered overvalued.

Waldencast PLC has a net margin of 18.82% compared to Hims & Hers Health's net margin of --. Hims & Hers Health's return on equity of 27.83% beat Waldencast PLC's return on equity of -9.22%.

Hims & Hers Health has a consensus price target of $25.21, signalling downside risk potential of -5.33%. On the other hand Waldencast PLC has an analysts' consensus of $5.76 which suggests that it could grow by 67.93%. Given that Waldencast PLC has higher upside potential than Hims & Hers Health, analysts believe Waldencast PLC is more attractive than Hims & Hers Health.

Hims & Hers Health has a beta of 1.309, which suggesting that the stock is 30.866% more volatile than S&P 500. In comparison Waldencast PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Waldencast PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health pays -- of its earnings as a dividend. Waldencast PLC pays out -- of its earnings as a dividend.

Hims & Hers Health quarterly revenues are $401.6M, which are larger than Waldencast PLC quarterly revenues of --. Hims & Hers Health's net income of $75.6M is higher than Waldencast PLC's net income of --. Notably, Hims & Hers Health's price-to-earnings ratio is 60.52x while Waldencast PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 4.88x versus 1.45x for Waldencast PLC. Usually stocks with elevated PS ratios are considered overvalued.